Tags

Type your tag names separated by a space and hit enter

Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease.
Arterioscler Thromb Vasc Biol. 1999 Jan; 19(1):23-7.AT

Abstract

Oxidation of low density lipoproteins (LDL) obviously plays an important role in the pathogenesis of atherosclerosis. The purpose of the study was to determine whether antibodies against oxidized LDL are associated with coronary artery disease (CAD). We determined the serum levels of antibodies against copper-oxidized LDL by enzyme-linked immunosorbent assay in 58 patients with angiographically verified CAD and 34 controls without CAD. The mean antibody level, expressed in optical density units, was significantly higher in patients than in controls (0.150+/-0.088 versus 0.094+/-0.054, respectively; P=0.00089). In logistic regression analysis, high antibody level against oxidized LDL was associated significantly with CAD (P=0.0114), independent of age (P=0.00137), gender (P=0.0021), body mass index (P=0.5947), triglyceride concentration (P=0.9813), and total cholesterol-high density lipoprotein (HDL) cholesterol (P=0.0080) group. Similar analysis in nondiabetic subjects (n=79) and in men only (n=75) showed analogous results, with only minor changes in P values. The antibody level against oxidized LDL differed significantly between nonsmokers and smokers in CAD patients (P<0.00197) but not in controls (P=NS). In addition, the antibody level against oxidized LDL differed significantly between nonsmokers and smokers in subjects with low HDL cholesterol (</=0.9 mmol/L) but not in subjects with high HDL cholesterol (>0.9 mmol/L). In conclusion, elevated levels of antibodies against oxidized LDL were associated with CAD. The data suggest that oxidized LDL plays a role in the pathogenesis of atherosclerosis and suggest a protective function for HDL against LDL oxidation.

Authors+Show Affiliations

Department of Medical Biochemistry, University of Tampere Medical School, Tampere University Hospital, Tampere City, Finland. terho.lehtimaki@tays.fiNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9888862

Citation

Lehtimäki, T, et al. "Autoantibodies Against Oxidized Low Density Lipoprotein in Patients With Angiographically Verified Coronary Artery Disease." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 19, no. 1, 1999, pp. 23-7.
Lehtimäki T, Lehtinen S, Solakivi T, et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol. 1999;19(1):23-7.
Lehtimäki, T., Lehtinen, S., Solakivi, T., Nikkilä, M., Jaakkola, O., Jokela, H., Ylä-Herttuala, S., Luoma, J. S., Koivula, T., & Nikkari, T. (1999). Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 19(1), 23-7.
Lehtimäki T, et al. Autoantibodies Against Oxidized Low Density Lipoprotein in Patients With Angiographically Verified Coronary Artery Disease. Arterioscler Thromb Vasc Biol. 1999;19(1):23-7. PubMed PMID: 9888862.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. AU - Lehtimäki,T, AU - Lehtinen,S, AU - Solakivi,T, AU - Nikkilä,M, AU - Jaakkola,O, AU - Jokela,H, AU - Ylä-Herttuala,S, AU - Luoma,J S, AU - Koivula,T, AU - Nikkari,T, PY - 1999/1/15/pubmed PY - 1999/1/15/medline PY - 1999/1/15/entrez SP - 23 EP - 7 JF - Arteriosclerosis, thrombosis, and vascular biology JO - Arterioscler. Thromb. Vasc. Biol. VL - 19 IS - 1 N2 - Oxidation of low density lipoproteins (LDL) obviously plays an important role in the pathogenesis of atherosclerosis. The purpose of the study was to determine whether antibodies against oxidized LDL are associated with coronary artery disease (CAD). We determined the serum levels of antibodies against copper-oxidized LDL by enzyme-linked immunosorbent assay in 58 patients with angiographically verified CAD and 34 controls without CAD. The mean antibody level, expressed in optical density units, was significantly higher in patients than in controls (0.150+/-0.088 versus 0.094+/-0.054, respectively; P=0.00089). In logistic regression analysis, high antibody level against oxidized LDL was associated significantly with CAD (P=0.0114), independent of age (P=0.00137), gender (P=0.0021), body mass index (P=0.5947), triglyceride concentration (P=0.9813), and total cholesterol-high density lipoprotein (HDL) cholesterol (P=0.0080) group. Similar analysis in nondiabetic subjects (n=79) and in men only (n=75) showed analogous results, with only minor changes in P values. The antibody level against oxidized LDL differed significantly between nonsmokers and smokers in CAD patients (P<0.00197) but not in controls (P=NS). In addition, the antibody level against oxidized LDL differed significantly between nonsmokers and smokers in subjects with low HDL cholesterol (</=0.9 mmol/L) but not in subjects with high HDL cholesterol (>0.9 mmol/L). In conclusion, elevated levels of antibodies against oxidized LDL were associated with CAD. The data suggest that oxidized LDL plays a role in the pathogenesis of atherosclerosis and suggest a protective function for HDL against LDL oxidation. SN - 1079-5642 UR - https://www.unboundmedicine.com/medline/citation/9888862/Autoantibodies_against_oxidized_low_density_lipoprotein_in_patients_with_angiographically_verified_coronary_artery_disease_ L2 - http://www.ahajournals.org/doi/full/10.1161/01.atv.19.1.23?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -